Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment

Overview of attention for article published in Clinical Breast Cancer, October 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 25 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 11,446 followers.

DCISionRT testing could potentially be a cost-effective strategy compared to traditional decision making for ductal carcinoma-in-situ treatments, optimizing radiotherapy benefit based on an accurate recurrence risk assessment. With PittGIM's @kenjsmith_…

RT @Sushilberiwal: Prelude for DCIS ⁦@CShahMD⁩ ⁦@ErinGillespieMD⁩ ⁦@UPMCHillmanCC⁩ https://t.co/8eXxSsPT2i

#radiotherapy

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.